Alpha Tau Medical
Sector: Healthcare & Life Sciences
About Alpha Tau Medical
Minimizes damage to healthy surrounding tissue, offering a new hope for aggressive solid cancers.
Products
Alpha DaRT™; Precision Delivery System
The Alpha DaRT™ technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, in order to overcome the short-range limitation of alpha particles. The extended range to which the alpha radiation can reach enables the potential treatment of the entire tumor. The Alpha DaRT technology is based on small, extremely precise amounts of radioactive radium-224 affixed to metal sources that are inserted into the tumor itself. When radium-224 decays, it releases radioactive atoms with short lifespans that diffuse inside the tumor. These atoms emit short-range alpha radiation that damages and kills cancer cells within a short period of time.
Latest Company Updates
- Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
- Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
- Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
- Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study